Burt Wealth Advisors lessened its position in Bristol-Myers Squibb (NYSE: BMY – Get Rating) by 3.8% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,503 shares of the biopharmaceutical company stock after selling 215 shares during the quarter. Burt Wealth Advisors’ holdings in Bristol-Myers Squibb were worth $ 402,000 at the end of the most recent reporting period.
Several other institutional investors have also recently added to or reduced their stakes in the company. Mizuho Securities Co. Ltd. increased its stake in Bristol-Myers Squibb by 239.0% in the 1st quarter. Mizuho Securities Co. Ltd. now owns 339 shares of the biopharmaceutical company stock worth $ 25,000 after buying an additional 239 shares during the period. New England Professional Planning Group Inc. purchased a new position in Bristol-Myers Squibb in the 1st quarter worth about $ 220,000. Horan Securities Inc. purchased a new position in Bristol-Myers Squibb in the 4th quarter worth about $ 29,000. Steward Financial Group LLC purchased a new position in Bristol-Myers Squibb in the 4th quarter worth about $ 29,000. Finally, Guardian Wealth Management Inc. purchased a new position in Bristol-Myers Squibb in the 4th quarter worth about $ 32,000. Hedge funds and other institutional investors own 73.07% of the company stock.
Shares of Bristol-Myers Squibb stock opened at $ 79.98 on Tuesday. The firm’s 50 day moving average price is $ 76.03 and its 200-day moving average price is $ 70.46. The company has a quick ratio of 1.23, a current ratio of 1.32 and a debt-to-equity ratio of 1.18. Bristol-Myers Squibb has a 52-week low of $ 53.22 and a 52-week high of $ 80.59. The company has a market cap of $ 170.28 billion, a P / E ratio of 28.36, a PEG ratio of 1.67 and a beta of 0.49.
Bristol-Myers Squibb (NYSE: BMY – Get Rating) last issued its quarterly earnings data on Friday, April 29th. The biopharmaceutical company reported $ 1.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $ 1.92 by $ 0.04. The firm had revenue of $ 11.65 billion for the quarter, compared to the consensus estimate of $ 11.34 billion. Bristol-Myers Squibb had a net margin of 13.31% and a return on equity of 48.37%. The company quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $ 1.74 EPS. As a group, equities research analysts forecast that Bristol-Myers Squibb will post 7.56 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Monday, August 1st. Investors of record on Friday, July 1st will be paid a $ 0.54 dividend. This represents a $ 2.16 dividend on an annualized basis and a yield of 2.70%. The ex-dividend date of this dividend is Thursday, June 30th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 76.60%.
In related news, CEO Giovanni Caforio sold 30,000 shares of Bristol-Myers Squibb stock in a transaction that occurred on Monday, June 13th. The shares were sold at an average price of $ 74.04, for a total value of $ 2,221,200.00. Following the completion of the sale, the chief executive officer now directly owns 551,104 shares in the company, valued at approximately $ 40,803,740.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Sandra Leung sold 65,000 shares of Bristol-Myers Squibb stock in a transaction that occurred on Monday, June 6th. The shares were sold at an average price of $ 74.89, for a total transaction of $ 4,867,850.00. Following the sale, the executive vice president now owns 308,627 shares of the company stock, valued at $ 23,113,076.03. The disclosure for this sale can be found here. 0.09% of the stock is owned by company insiders.
Several research firms recently commented on BMY. Bank of America raised their price target on shares of Bristol-Myers Squibb from $ 78.00 to $ 80.00 and gave the stock a “buy” rating in a research note on Monday, June 6th. Raymond James downgraded shares of Bristol-Myers Squibb from an “outperform” rating to a “market perform” rating in a research report on Friday, June 3rd. They noted that the move was a valuation call. Barclays raised their target price on shares of Bristol-Myers Squibb from $ 66.00 to $ 68.00 in a research report on Monday, May 2nd. Citigroup reissued a “buy” rating and set a $ 90.00 target price on shares of Bristol-Myers Squibb in a research report on Friday, June 3rd. Finally, Morgan Stanley cut their target price on shares of Bristol-Myers Squibb from $ 66.00 to $ 64.00 and set an “underweight” rating on the stock in a research report on Wednesday, April 6th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Bristol-Myers Squibb currently has a consensus rating of “Moderate Buy” and an average target price of $ 74.27.
About Bristol-Myers Squibb: (Get Rating)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke / systemic embolism in NVAF, and for the treatment of DVT / PE; Opdivo for anti-cancer indications; Pomalyst / Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.
Receive News & Ratings for Bristol-Myers Squibb Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bristol-Myers Squibb and related companies with MarketBeat.com’s FREE daily email newsletter.